Linda Simmler received her degree in Pharmacy from the University of Basel, where she also obtained her PhD in Pharmacology in 2013, investigating amphetamine-type designer drugs in the laboratory of Prof. Matthias Liechti. From 2013 to 2015, Linda Simmler was a post-doctoral fellow at Vanderbilt University in Nashville, USA, in the laboratory of Prof. Randy Blakely and supported by the Swiss National Science Foundation (SNSF). She investigated serotonin-mediated effects of cocaine using a knock-in mouse model with a cocaine-insensitive serotonin-transporter. In 2016, Simmler joined the laboratory of Prof. Christian Lüscher, where she obtained a SNSF Ambizione grant: She continued her research on drugs of abuse, focusing on drug-induced synaptic changes and the potential of psychoactive substances like ketamine for the treatment of psychiatric disorders. In 2022, Linda Simmler obtained a competitive SNSF Starting Grant. Since August 2023, she directs the Neuropharmacology research group, focusing her research on synaptic plasticity in the context of antidepressant effects of psilocybin and other hallucinogens.